advertising
-
1
Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. J Am Acad Dermatol 38: 702, 1998.
-
2
Elewski BE: The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 36: 754, 1997.
-
3
Lubeck DP: Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 38: S64, 1998.
-
4
Lubeck DP, Patrick DL, McNulty P, et al: Quality of life of persons with onychomycosis. Qual Life Res 2: 341, 1993.
-
5
Boyko EJ, Ahroni JH, Cohen V, et al: Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 29: 1202, 2006.
-
6
Roujeau JC, Sigurgeirsson B, Korting HC, et al: Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 209: 301, 2004.
-
7
Gupta AK, Jain HC, Lynde CW, et al: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43: 244, 2000.
-
8
Sigurgeirsson B, Steingrimsson O: Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 18: 48, 2004.
-
9
Svejgaard EL, Nilsson J: Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47: 131, 2004.
-
10
Gupta AK, Konnikov N, MacDonald P, et al: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 139: 665, 1998.
-
11
Gupta AK, Gupta MA, Summerbell RC, et al: The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 14: 466, 2000.
-
12
Güleç AT, Demirbilek M, Seckin D, et al: Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol 49: 187, 2003.
-
13
Gupta AK, Taborda P, Taborda V, et al: Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 39: 746, 2000.
-
14
Gupta AK, Lynde CW, Jain HC, et al: A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 136: 786, 1997.
-
15
Sigurgeirsson B, Baran R: The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol 28: 1480, 2014.
-
16
Koshnick RL, Lilly KK, St Clair K, et al: Use of diagnostic tests by dermatologists, podiatrists and family practitioners in the United States: pilot data from a cross-sectional survey. Mycoses 50: 463, 2007.
-
17
Schein JR, Gause D, Stier DM, et al: Onychomycosis: baseline results of an observational study. JAPMA 87: 512, 1997.
-
18
Lubeck DP, Schein JR, Gause D, et al: Health-related quality of life in patients with toenail onychomycosis: data from a 9-month observational study. J Clin Outcomes Manag 6: 37, 1999.
-
19
Scher RK, Tosti A, Joseph WS, et al: Onychomycosis diagnosis and management: perspectives from a joint dermatology-podiatry roundtable. J Drugs Dermatol 14, 2015, in press.
-
20
Garcia-Doval I, Cabo F, Monteagudo B, et al: Clinical diagnosis of toenail onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol 163: 743, 2010.
-
21
Fletcher CL, Hay RJ, Smeeton NC: Onychomycosis: the development of a clinical diagnostic aid for toenail disease: part I. Establishing discriminating historical and clinical features. Br J Dermatol 150: 701, 2004.
-
22
Allevato MA: Diseases mimicking onychomycosis. Clin Dermatol 28: 164, 2010.
-
23
Rich P, Elewski B, Scher RK, et al: Diagnosis, clinical implications, and complications of onychomycosis. Semin Cutan Med Surg 32(suppl 1): S5, 2013.
-
24
Scher RK, Tavakkol A, Sigurgeirsson B, et al: Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 56: 939, 2007.
-
25
Tchernev G, Penev PK, Nenoff P, et al: Onychomycosis: modern diagnostic and treatment approaches. Wien Med Wochenschr 163: 1, 2013.
-
26
Karimzadegan-Nia M, Mir-Amin-Mohammadi A, Bouzari N, et al: Comparison of direct smear, culture and histology for the diagnosis of onychomycosis. Australas J Dermatol 48: 18, 2007.
-
27
Lawry MA, Haneke E, Strobeck K, et al: Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 136: 1112, 2000.
-
28
Lipner S, Scher RK: Onychomycosis: current and future therapies. Cutis 93: 60, 2014.
-
29
Daniel CR III, Gupta AK, Daniel MP, et al: Two feet-one hand syndrome: a retrospective multicenter survey. Int J Dermatol 36: 658, 1997.
-
30
Ghannoum MA, Mukherjee PK, Warshaw EM, et al: Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis 91: 237, 2013.
-
31
Szepietowski JC, Reich A, Garlowska E, et al: Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 142: 1279, 2006.
-
32
Lamisil [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
-
33
Sporonox [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2012.
-
34
Scher RK, Breneman D, Rich P, et al: Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38: S77, 1998.
-
35
Yan J, Wang X, Chen S: Systematic review of severe acute liver injury caused by terbinafine. Int J Clin Pharm 36: 679, 2014.
-
37
Gupta AK, Joseph WS: Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. JAPMA 90: 495, 2000.
-
38
Elewski BE, Tosti A: Tavaborole for the treatment of onychomycosis. Expert Opin Pharmacother 15: 1439, 2014.
-
39
Kerydin [package insert]. Palo Alto, CA: Anacor Pharmaceuticals; 2014.
-
40
JoSiu WJ, Tatsumi Y, Senda H, et al: Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother 57: 1610, 2013.
-
41
Jarratt M, Siu WJ, Yamakawa E, et al: Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol 12: 1010, 2013.
-
42
Jublia [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014.
-
43
Elewski B, Pariser D, Rich P, et al: Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg 32(suppl 1): S9, 2013.
-
44
Landsman AS, Robbins AH, Angelini PF, et al: Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. JAPMA 100: 166, 2010.
-
45
Landsman AS, Robbins AH: Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days. JAPMA 102: 169, 2012.
-
46
Zhang RN, Wang DK, Zhuo FL, et al: Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J (Engl) 125: 3288, 2012.
-
47
Hochman LG: Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 13: 2, 2011.
-
48
Kozarev J, Vižintin Z: Novel laser therapy in treatment of onychomycosis. J Laser Health Acad 2010: 1, 2010.
-
49
Kozarev J: ClearSteps—laser onychomycosis treatment: assessment of efficacy 12 months after treatment and beyond. J Laser Health Acad 2011: S07, 2011.
-
50
Kimura U, Takeuchi K, Kinoshita A, et al: Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd:YAG laser using a 5 mm spot diameter. J Drugs Dermatol 11: 496, 2012.
-
51
Waibel J, Wulkan AJ, Rudnick A: Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol 12: 1237, 2013.
-
52
Kalokasidis K, Onder M, Trakatelli MG, et al: The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract 2013: 379725, 2013.
-
53
Gupta AK, Simpson FC: Laser therapy for onychomycosis. J Cutan Med Surg 17: 301, 2013.
-
54
Malay DS, Yi S, Borowsky P, et al: Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg 48: 294, 2009.
-
55
Potter LP, Mathias SD, Raut M, et al: The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat 18: 46, 2007.
-
56
Jennings MB, Pollak R, Harkless LB, et al: Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. JAPMA 96: 465, 2006.
-
57
Elewski BE, Rich P, Tosti A, et al: Onchomycosis: an overview. J Drugs Dermatol 12: s96, 2013.
-
58
Sigurgeirsson B: Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venereol 24: 679, 2010.
-
59
Gupta AK, Cooper EA, Paquet M: Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J Cutan Med Surg 17: 201, 2013.
-
60
Avner S, Nir N, Henri T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 16: 327, 2005.
-
61
Baran R, Sigurgeirsson B, de Berker D, et al: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 157: 149, 2007.
-
62
Lecha M: Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol 145(suppl 60): 21, 2001.
-
63
Piraccini BM, Sisti A, Tosti A: Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 62: 411, 2010.
-
64
Sigurgeirsson B, Olafsson JH, Steinsson JT, et al: Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 24: 910, 2010.
-
65
Tosti A, Piraccini BM, Stinchi C, et al: Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 197: 162, 1998.
-
66
Sigurgeirsson B, Olafsson JH, Steinsson JB, et al: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138: 353, 2002.
-
67
Gazes MI, Zeichner J: Onychomycosis in close quarter living review of the literature. Mycoses 56: 610, 2013.
Diagnosis and Management of Onychomycosis
Perspectives from a Joint Podiatric Medicine–Dermatology Roundtable
Search for other papers by Tracey C. Vlahovic in
Current site
Google Scholar
PubMed
Search for other papers by Warren S. Joseph in
Current site
Google Scholar
PubMed
Search for other papers by Richard K. Scher in
Current site
Google Scholar
PubMed
Search for other papers by Antonella Tosti in
Current site
Google Scholar
PubMed
Search for other papers by Jesse Plasencia in
Current site
Google Scholar
PubMed
Search for other papers by David M. Pariser in
Current site
Google Scholar
PubMed
Search for other papers by Bryan C. Markinson in
Current site
Google Scholar
PubMed
Onychomycosis is a fungal infection, and, as such, one of the goals of treatment should be eradication of the infective agent. Despite this, in contrast to dermatologists, many podiatric physicians do not include antifungals in their onychomycosis treatment plans. Before initiating treatment, confirmation of mycologic status via laboratory testing (eg, microscopy with potassium hydroxide preparation, histopathology with periodic acid–Schiff staining, fungal culture, and polymerase chain reaction) is important; however, more podiatric physicians rely solely on clinical signs than do dermatologists. These dissimilarities may be due, in part, to differences between specialties in training, reimbursement patterns, or practice orientation, and to explore these differences further, a joint podiatric medicine–dermatology roundtable was convened. In addition, treatment options have been limited owing to safety concerns with available oral antifungals and relatively low efficacy with previously available topical treatments. Recently approved topical treatments—efinaconzole and tavaborole—offer additional options for patients with mild-to-moderate disease. Debridement alone has no effect on mycologic status, and it is recommended that it be used in combination with an oral or topical antifungal. There is little to no clinical evidence to support the use of lasers or over-the-counter treatments for onychomycosis. After a patient has achieved cure (absence of clinical signs or absence of fungus with minimal clinical signs), lifestyle and hygiene measures, prophylactic/maintenance treatment, and proactive treatment for tinea pedis, including in family members, may help maintain this status.
advertising
advertising
